CytomX Therapeutics

REIMAGINING THERAPEUTIC ANTIBODIES

Goldman Sachs 40th Annual Global Healthcare Conference

JUNE 12, 2019

Forward Looking Statement

This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of preclinical studies and clinical trials and other development activities; the uncertainties inherent in the initiation and enrollment of clinical trials; expectations of expanding on-going clinical trials; availability and timing of data from clinical trials; the unpredictability of the duration and results of regulatory review; market acceptance for approved products and innovative therapeutic treatments; competition; the potential not to receive partnership milestone, profit sharing or royalty payments; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. More information concerning us and such risks and uncertainties is available on our website and in our press releases and in our public filings with the U.S. Securities and Exchange Commission. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

This presentation concerns products that have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). No representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

Reimagining Therapeutic Antibodies

ANTIBODIES ARE A SUCCESSFUL CLASS OF THERAPEUTICS

- Powerful, potent modalities; > $100 billion WW sales 2018
- Potency can be a liability for widely distributed targets
- Major opportunity to improve targeting and localize antibody pharmacology

CYTOMX PROBODY™ PLATFORM IS DESIGNED TO LOCALIZE TARGET BINDING TO TUMOR

- Maintaining potency
- Reducing side effects
- Enabling new target opportunities

PROBODY PLATFORM BUILT ON A DECADE OF "HIGH SCIENCE" RESEARCH AT CYTOMX

- Deep knowledge of tumor microenvironment biology
- Innovative antibody engineering and IP to create Probody therapeutics, a unique class of localized, antibody prodrugs



CytomX Therapeutics

Integrated Clinical and Translational Data Support Probody Platform Proof-of-Concept



- **Robust translation of preclinical data into clinical setting**
- **CX-072 has unique molecular & clinical pharmacology**
- **New paradigm for therapeutic antibodies**



Clinical imaging
Stage IV Anaplastic Thyroid Cancer, 4 days post-injection

Primary tumor
Metastases



Collaboration with Professor E. G. E. de Vries, University Medical Center Groningen, The Netherlands

CytomX Therapeutics

CX-2009 is an Investigational First-in-Class Anti-CD166 Probody Drug Conjugate with Broad Market Potential

- CD166 is highly expressed in many cancers
  - Including breast, lung, ovarian, head and neck
  - Undruggable with conventional approaches due to normal tissue expression
- Probody platform enables the potential development of this attractive target with CX-2009
  - Masking technology limits binding to normal tissues
  - Potent SPDB-DM4 payload (microtubule inhibitor)



PROCLAIM CX-2009

Single Agent Activity for CX-2009 Observed in Phase 1 Dose Escalation



As of February 26, 2019 data snapshot
Presented at AACR 2019

July 16, 2018 **BASELINE**	September 11, 2018 **3 DOSES**	November 12, 2018 **6 DOSES**



New lesion observed. Progression noted.

Case Study: Pembrolizumab-refractory TNBC Patient at 8 mg/kg